リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「JNK pathway plays a critical role for expansion of human colorectal cancer in the context of BRG1 suppression」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

JNK pathway plays a critical role for expansion of human colorectal cancer in the context of BRG1 suppression

Yoshikawa, Takaaki Fukuda, Akihisa Omatsu, Mayuki Namikawa, Mio Sono, Makoto Fukunaga, Yuichi Masuda, Tomonori Araki, Osamu Nagao, Munemasa Ogawa, Satoshi Masuo, Kenji Goto, Norihiro Hiramatsu, Yukiko Muta, Yu Tsuda, Motoyuki Maruno, Takahisa Nakanishi, Yuki Kawada, Kenji Takaishi, Shigeo Seno, Hiroshi 京都大学 DOI:10.1111/cas.15520

2022.10

概要

Tumor stem cells (TSCs), capable of self-renewal and continuous production of progeny cells, could be potential therapeutic targets. We have recently reported that chromatin remodeling regulator Brg1 is required for maintenance of murine intestinal TSCs and stemness feature of human colorectal cancer (CRC) cells by inhibiting apoptosis. However, it is still unclear how BRG1 suppression changes the underlying intracellular mechanisms of human CRC cells. We found that Brg1 suppression resulted in upregulation of the JNK signaling pathway in human CRC cells and murine intestinal TSCs. Simultaneous suppression of BRG1 and the JNK pathway, either by pharmacological inhibition or silencing of c-JUN, resulted in even stronger inhibition of the expansion of human CRC cells compared to Brg1 suppression alone. Consistently, high c-JUN expression correlated with worse prognosis for survival in human CRC patients with low BRG1 expression. Therefore, the JNK pathway plays a critical role for expansion and stemness of human CRC cells in the context of BRG1 suppression, and thus a combined blockade of BRG1 and the JNK pathway could be a novel therapeutic approach against human CRC.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-­424.

2. Jung G, Hernandez-­Illan E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17:111-­130.

3. Vaiopoulos AG, Athanasoula K, Papavassiliou AG. Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges. Biochim Biophys Acta. 2014;1842:971-­980.

4. Euskirchen G, Auerbach RK, Snyder M. SWI/SNF chromatin-­ remodeling factors: multiscale analyses and diverse functions. J Biol Chem. 2012;287:30897-­3 0905.

5. Shen J, Peng Y, Wei L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5:752-­767.

6. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11:481-­492.

7. Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-­deficient sarcomas. Nat Genet. 2015;47:1200-­1205.

8. Matsubara D, Kishaba Y, Ishikawa S, et al. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci. 2013;104:266-­273.

9. Tischkowitz M, Huang S, Banerjee S, et al. Small-­cell carcinoma of the ovary, hypercalcemic type-­genetics, new treatment targets, and current management guidelines. Clin Cancer Res. 2020;26:3908-­3917.

10. Guerrero-­Martinez JA, Reyes JC. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer. Sci Rep. 2018;8:2043.

11. Sun A, Tawfik O, Gayed B, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate. 2007;67:203-­213.

12. Lin S, Jiang T, Ye L, et al. The chromatin-­remodeling enzyme BRG1 promotes colon cancer progression via positive regulation of WNT3A. Oncotarget. 2016;7:86051-­86063.

13. Pyo JS, Son BK, Oh D, Kim EK. BRG1 is correlated with poor prognosis in colorectal cancer. Hum Pathol. 2018;73:66-­73.

14. Tsuda M, Fukuda A, Roy N, et al. The BRG1/SOX9 axis is critical for acinar cell-­derived pancreatic tumorigenesis. J Clin Invest. 2018;128:3475-­3 489.

15. Watanabe T, Semba S, Yokozaki H. Regulation of PTEN expression by the SWI/SNF chromatin-­remodelling protein BRG1 in human colorectal carcinoma cells. Br J Cancer. 2011;104:146-­154.

16. Yoshikawa T, Fukuda A, Omatsu M, et al. Brg1 is required to maintain colorectal cancer stem cells. J Pathol. 2021;255:257-­269.

17. Nakanishi Y, Seno H, Fukuoka A, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet. 2013;45:98-­103.

18. Sumi-­Ichinose C, Ichinose H, Metzger D, Chambon P. SNF2beta-­ BRG1 is essential for the viability of F9 murine embryonal carcinoma cells. Mol Cell Biol. 1997;17:5976-­5986.

19. Solar M, Cardalda C, Houbracken I, et al. Pancreatic exocrine duct cells give rise to insulin-­producing beta cells during embryogenesis but not after birth. Dev Cell. 2009;17:849-­860.

20. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-­Jun mediated by MAP kinases. Nature. 1991;353:670-­674.

21. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-­terminal kinase. Proc Natl Acad Sci U S A. 2001;98:13681-­13686.

22. Sancho R, Nateri AS, de Vinuesa AG, et al. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J. 2009;28:1843-­1854.

23. Okada M, Shibuya K, Sato A, et al. Targeting the K-­Ras-­-­JNK axis eliminates cancer stem-­like cells and prevents pancreatic tumor formation. Oncotarget. 2014;5:5100-­5112.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る